ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.386
-0.022 (-5.42%)
At close: Nov 20, 2024, 4:00 PM
0.396
+0.010 (2.51%)
After-hours: Nov 20, 2024, 6:25 PM EST

Company Description

ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies.

The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies.

It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.

The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection.

In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development.

Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes.

Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services.

The company is headquartered in Victoria, Canada.

ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies logo
Country Canada
Founded 1983
IPO Date Jan 3, 2017
Industry Biotechnology
Sector Healthcare
Employees 101
CEO Jennifer Bath

Contact Details

Address:
3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada
Phone 250 483 0308
Website ipatherapeutics.com

Stock Details

Ticker Symbol IPA
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency CAD
CIK Code 0001715925
CUSIP Number 45257F200
ISIN Number CA45257F2008
SIC Code 2834

Key Executives

Name Position
Dr. Jennifer Lynne Bath Ph.D. Chief Executive Officer, President and Non-Independent Director
Kristin Taylor CPA, M.B.A. Chief Financial Officer
Dr. Ilse Roodink Chief Scientific Officer and Interim General Manager of IPA Europe, Oss
Kari Graber Vice President of Commercial Services
Dr. Roland Romijn Head of General Operations of the Utrecht site of IPA (Europe)

Latest SEC Filings

Date Type Title
Nov 18, 2024 6-K Report of foreign issuer
Nov 13, 2024 6-K Report of foreign issuer
Nov 4, 2024 6-K Report of foreign issuer
Oct 28, 2024 6-K Report of foreign issuer
Oct 24, 2024 6-K Report of foreign issuer
Oct 21, 2024 6-K Report of foreign issuer
Oct 11, 2024 6-K Report of foreign issuer
Oct 10, 2024 6-K Report of foreign issuer
Oct 2, 2024 6-K Report of foreign issuer
Sep 26, 2024 6-K Report of foreign issuer